Better understanding and treating myeloma is the focus of eight research projects that are part of the Leukaemia Foundation’s National Research Program.
The Pharmaceutical Benefits Advisory Committee (PBAC) considered four blood cancer treatments at its March 2020 meeting including a drug for myeloma – plitidepsin (Aplidin®).
More than 600 Australians have a potentially life-saving stem cell transplant each year.
Australians with ALL and minimal residual disease (MRD) can now access blinatumomab on the PBS.
Making a difference to the lives of her patients is why Dr Wei Jiang gets up each morning.
“A few days before I was diagnosed, I went home after work and was pretty much unable to get upstairs without feeling really tired."
Seven years after being diagnosed with PV, Ken’s spleen suddenly ruptured.
How the MPNs are classified is set to change with eight new classifications based on the underlying mechanisms that drive the mutations.
Vince learnt of the concerningly low rates of referral for people at risk of amyloidosis.
A new class of drug may soon be available to Australian patients with significant cardiac AL amyloidosis
